$AMRN Amarin analyst commentary at Jefferies Amarin recent pullback a buying opportunity, says Jefferies. Jefferies analyst Michael Yee recommends using the recent pullback in shares of Amarin as a buying opportunity. Following a meeting with management, the analyst sees confidence around a good label for Vascepa that is broader than just primary prevention. Yee expects a "strong" 2020 launch, pointing out that Amarin has doubled its salesforce and are launching direct-to-consumer. In addition, Amarin could reach a patent settlement or end up winning the trial, says Yee, who keeps a Buy rating on the shares. Read more at: thefly.com/landingPageNews....
  • 6
  • 3